Cascade Metrix (CMX) is a medical technology company working within a new paradigm in critical care. The company will introduce an Automated Multiplex Analyzer ["AutoPlexer"] that will revolutionize the bedside testing of hospitalized patients whose care and recovery is dependent on repetitive, around-the-clock measurements of critical blood parameters. This innovative and proprietary ex-vivo blood analysis system is first being applied to the automated multiplex measurement of glucose, lactate, hemoglobin and oxygen saturation in critically ill patients.
Latest News: CMX is pleased to announce that it has been awarded a highly competitive SBIR Phase 1 grant funding (1R43GM146498-01; "A Multiplex Analyzer for Sepsis Management"; PI: Kislaya Kunjan) from National Institute of General Medical Sciences (NIGMS). Additional details on the project are available on the RePORTER.NIH.gov Portal. In addition to this, Elevate Ventures provides additional non-dilutive matching funds.
CMX is also actively exploring investment and partnership opportunities with firms in the medical technology and related areas. Please contact